EUVIMEDEUVIMED entdecken
Crossref

Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors

Hyehyun Jeong, Jeongryul Ryu, Jae Ho Jeong, Sangwon Han iD, Jaewon Hyung, Jin-Hee Ahn, Kyung Hae Jung, Sung-Bae Kim, Byung-Kwan Jeong, Hee Jin Lee, Gyungyub Gong, Dae Hyuk Moon

European Journal of Nuclear Medicine and Molecular Imaging · 2025-05 · 52 (6) · 2096-2106

DOI: 10.1007/s00259-024-07058-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 14.01.2025. Verfasst von Hyehyun Jeong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Positron Emission Tomography Computed Tomography, Cyclin-Dependent Kinase 6. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Korea Health Industry Development Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 4Positron Emission Tomography Computed TomographyCyclin-Dependent Kinase 6EstradiolProtein Kinase InhibitorsHumansFemaleMiddle AgedAgedRetrospective StudiesPrognosisAdultNeoplasm Metastasis

Stichwörter der Autor:innen

18F-FES PETBreast cancerCDK4/6 inhibitorsEndocrine therapyPredictive biomarker

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6EstradiolProtein Kinase Inhibitors16-fluoroestradiolCDK4 protein, humanCDK6 protein, human

Autor:innen und Institutionen

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. jaeho.jeong@amc.seoul.kr.
  • Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea. hswon87@naver.com.
  • Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Sangwon Han

Förderung

  • Korea Health Industry Development Institute

Zitieren

APA

Jeong, H., Ryu, J., Jeong, J. H., Han, S., Hyung, J., Ahn, J. H., Jung, K. H., Kim, S. B., Jeong, B. K., Lee, H. J., Gong, G., & Moon, D. H. (2025). Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors. European Journal of Nuclear Medicine and Molecular Imaging, 52(6), 2096-2106. https://doi.org/10.1007/s00259-024-07058-1

Vancouver

Jeong H, Ryu J, Jeong JH, Han S, Hyung J, Ahn JH, et al. Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(6):2096-2106. doi:10.1007/s00259-024-07058-1

BibTeX
@article{Jeong2025,
  author = {Jeong, Hyehyun and Ryu, Jeongryul and Jeong, Jae Ho and Han, Sangwon and Hyung, Jaewon and Ahn, Jin-Hee and Jung, Kyung Hae and Kim, Sung-Bae and Jeong, Byung-Kwan and Lee, Hee Jin and Gong, Gyungyub and Moon, Dae Hyuk},
  title = {Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {6},
  pages = {2096--2106},
  doi = {10.1007/s00259-024-07058-1}
}
Kostenlos starten →